Century Therapeutics, Inc. (IPSC)
NASDAQ$0.6076+0.01 (1.68%)
Market Cap
$50.7M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
395 of 924
Rank in Industry
232 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
IPSC Insider Trading Activity
IPSC Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $7,657 | 1 | 5 |
Sells | $122,300 | 21 | 95 |
Related Transactions
| Quimi Daphne | director | 1 | $7,657 | 0 | $0 | $7,657 |
| Carr Douglas | SVP Finance & Operations | 0 | $0 | 5 | $2,710 | $-2,710 |
| Farid Adrienne | Chief Operations Officer | 0 | $0 | 5 | $8,337 | $-8,337 |
| Pfeiffenberger Brent | President and CEO | 0 | $0 | 2 | $28,554 | $-28,554 |
| Russotti Gregory | See Remarks | 0 | $0 | 9 | $82,699 | $-82,699 |
About Century Therapeutics, Inc.
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, …
Insider Activity of Century Therapeutics, Inc.
Over the last 12 months, insiders at Century Therapeutics, Inc. have bought $7,657 and sold $122,300 worth of Century Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Century Therapeutics, Inc. have bought $16M and sold $2.71M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Quimi Daphne (director) — $7,657.
The last purchase of 5,000 shares for transaction amount of $7,657 was made by Quimi Daphne (director) on 2024‑09‑12.
List of Insider Buy and Sell Transactions, Century Therapeutics, Inc.
| 2025-03-10 | Sale | Pfeiffenberger Brent | President and CEO | 2,235 0.0027% | $0.61 | $1,375 | -2.17% | |
| 2025-03-10 | Sale | Carr Douglas | SVP Finance & Operations | 1,240 0.0015% | $0.61 | $763 | -2.17% | |
| 2025-03-10 | Sale | Russotti Gregory | See Remarks | 2,360 0.0028% | $0.61 | $1,451 | -2.17% | |
| 2025-03-10 | Sale | Farid Adrienne | Chief Operations Officer | 2,359 0.0028% | $0.61 | $1,451 | -2.17% | |
| 2025-02-18 | Sale | Pfeiffenberger Brent | President and CEO | 34,712 0.0413% | $0.78 | $27,180 | -19.75% | |
| 2025-02-03 | Sale | Carr Douglas | SVP Finance & Operations | 351 0.0004% | $0.78 | $274 | -9.35% | |
| 2025-02-03 | Sale | Farid Adrienne | Chief Operations Officer | 1,054 0.0012% | $0.78 | $822 | -9.35% | |
| 2024-11-04 | Sale | Carr Douglas | SVP Finance & Operations | 283 0.0003% | $1.23 | $347 | -21.03% | |
| 2024-11-04 | Sale | Farid Adrienne | Chief Operations Officer | 1,033 0.0012% | $1.23 | $1,267 | -21.03% | |
| 2024-09-12 | Quimi Daphne | director | 5,000 0.0059% | $1.53 | $7,657 | -20.78% | ||
| 2024-08-05 | Sale | Carr Douglas | SVP Finance & Operations | 289 0.0003% | $1.83 | $528 | -27.96% | |
| 2024-08-05 | Sale | Farid Adrienne | Chief Operations Officer | 1,073 0.0012% | $1.83 | $1,960 | -27.96% | |
| 2024-07-26 | Sale | Russotti Gregory | See Remarks | 586 0.0007% | $2.50 | $1,465 | -45.00% | |
| 2024-07-24 | Sale | Russotti Gregory | See Remarks | 1,600 0.002% | $2.52 | $4,029 | -41.60% | |
| 2024-07-23 | Sale | Russotti Gregory | See Remarks | 200 0.0002% | $2.50 | $500 | -43.95% | |
| 2024-06-20 | Sale | Russotti Gregory | See Remarks | 5,000 0.0052% | $2.84 | $14,179 | -45.72% | |
| 2024-06-05 | Sale | Russotti Gregory | See Remarks | 5,000 0.006% | $3.00 | $14,989 | -50.67% | |
| 2024-05-20 | Sale | Russotti Gregory | See Remarks | 5,000 0.006% | $3.00 | $14,978 | -49.17% | |
| 2024-05-06 | Sale | Russotti Gregory | See Remarks | 5,000 0.0076% | $3.12 | $15,619 | -51.42% | |
| 2024-05-03 | Sale | Carr Douglas | SVP Finance & Operations | 257 0.0004% | $3.11 | $798 | -49.17% |
Total: 36
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| Quimi Daphne | director | 5000 0.0059% | $2,981.50 | 1 | 0 | |
| BAYER AKTIENGESELLSCHAFT | 10 percent owner | 12675838 14.9077% | $7.56M | 1 | 0 | <0.0001% |
| Casdin Eli | director | 3206380 3.7709% | $1.91M | 1 | 0 | <0.0001% |
| Versant Venture Capital VI, L.P. | 10 percent owner | 714095 0.8398% | $425,814.85 | 1 | 0 | <0.0001% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$15,956,086 | 53 | 5.33% | $46.1M | |
$81,638,324 | 48 | 7.58% | $49.31M | |
$18,274,594 | 22 | -26.07% | $49.68M | |
$1,087,418 | 21 | 1.95% | $45.39M | |
$160,539,875 | 21 | -6.57% | $46.76M |
IPSC Institutional Investors: Active Positions
| Increased Positions | 44 | +75.86% | 6M | +15.83% |
| Decreased Positions | 20 | -34.48% | 7M | -16.72% |
| New Positions | 15 | New | 1M | New |
| Sold Out Positions | 10 | Sold Out | 2M | Sold Out |
| Total Postitions | 82 | +41.38% | 40M | -0.89% |
IPSC Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Bain Capital Life Sciences Investors, Llc | $3,225.00 | 6.37% | 5.41M | 0 | 0% | 2024-12-31 |
| Casdin Capital, Llc | $3,094.00 | 6.11% | 5.19M | +2M | +61.58% | 2024-12-31 |
| Vr Adviser, Llc | $2,358.00 | 4.66% | 3.96M | -1M | -26.57% | 2024-12-31 |
| Boxer Capital, Llc | $2,324.00 | 4.59% | 3.9M | -1M | -20.43% | 2024-09-30 |
| Blackrock, Inc. | $1,810.00 | 3.57% | 3.04M | +47,328 | +1.58% | 2024-12-31 |
| Fmr Llc | $1,510.00 | 2.98% | 2.53M | +12,363 | +0.49% | 2024-12-31 |
| Vanguard Group Inc | $1,419.00 | 2.8% | 2.38M | -93,508 | -3.78% | 2024-12-31 |
| Dafna Capital Management Llc | $1,016.00 | 2.01% | 1.7M | 0 | 0% | 2024-12-31 |
| Millennium Management Llc | $958.00 | 1.89% | 1.61M | +1M | +1,041.79% | 2024-12-31 |
| Syncona Portfolio Ltd | $723.00 | 1.43% | 1.21M | 0 | 0% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.